tetano
Editor, Senior Moderator
J Pediatric Infect Dis Soc
. 2023 Mar 17;piac124.
doi: 10.1093/jpids/piac124. Online ahead of print.
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study
Gilad Sherman[SUP] 1 2 [/SUP], Gabriella S Lamb[SUP] 1 2 [/SUP], Tanvi S Sharma[SUP] 1 2 [/SUP], Elizabeth C Lloyd[SUP] 3 [/SUP], Jerod Nagel[SUP] 4 [/SUP], Nada N Dandam[SUP] 4 [/SUP], Carlos R Oliveira[SUP] 5 [/SUP], Hassan S Sheikha[SUP] 5 [/SUP], Brenda I Anosike[SUP] 6 [/SUP], Philip Lee[SUP] 6 [/SUP], Surabhi B Vora[SUP] 7 [/SUP], Karisma Patel[SUP] 8 [/SUP], Paul K Sue[SUP] 8 [/SUP], Beenish Rubbab[SUP] 8 [/SUP], April M Yarbrough[SUP] 9 [/SUP], Lakshmi Ganapathi[SUP] 1 2 [/SUP], Mari M Nakamura[SUP] 1 2 10 [/SUP]
Affiliations
Abstract
Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.
Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.
. 2023 Mar 17;piac124.
doi: 10.1093/jpids/piac124. Online ahead of print.
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study
Gilad Sherman[SUP] 1 2 [/SUP], Gabriella S Lamb[SUP] 1 2 [/SUP], Tanvi S Sharma[SUP] 1 2 [/SUP], Elizabeth C Lloyd[SUP] 3 [/SUP], Jerod Nagel[SUP] 4 [/SUP], Nada N Dandam[SUP] 4 [/SUP], Carlos R Oliveira[SUP] 5 [/SUP], Hassan S Sheikha[SUP] 5 [/SUP], Brenda I Anosike[SUP] 6 [/SUP], Philip Lee[SUP] 6 [/SUP], Surabhi B Vora[SUP] 7 [/SUP], Karisma Patel[SUP] 8 [/SUP], Paul K Sue[SUP] 8 [/SUP], Beenish Rubbab[SUP] 8 [/SUP], April M Yarbrough[SUP] 9 [/SUP], Lakshmi Ganapathi[SUP] 1 2 [/SUP], Mari M Nakamura[SUP] 1 2 10 [/SUP]
Affiliations
- PMID: 36928172
- DOI: 10.1093/jpids/piac124
Abstract
Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.
Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.